Mariner
AUTL

Mariner’s Autolus Therapeutics AUTL Stock Holding History

Mariner’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,322
Closed -$16.8K – 3550
2025
Q3 		$16.8K Sell
10,322
-8,625
-46% -$16.9K ﹤0.01% 3521
2025
Q2 		$43.2K Buy
+18,947
New +$31.3K ﹤0.01% 3362
2023
Q3 		– Sell
-101,000
Closed -$240K – 2906
2023
Q2 		$240K Buy
+101,000
New +$240K ﹤0.01% 2304

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Mariner's AUTL Position: Q4 2025 in Review

Mariner sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 10,322 shares — an estimated $16.8K sold.

Mariner first reported a position in AUTL in Q2 2023 and held it in 3 quarters. The position peaked at $240K in Q2 2023. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • Mariner reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mariner sold 10,322 Autolus Therapeutics shares in Q4 2025, an estimated $16.8K.
  • Mariner first reported a position in Autolus Therapeutics in Q2 2023 and held it in 3 quarters.
  • Mariner's Autolus Therapeutics position peaked at $240K in Q2 2023.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.